Jacquelyn Sumer
Compliance Officer presso CULLINAN THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Jacquelyn Sumer is currently working as the Secretary, Chief Legal & Compliance Officer at Cullinan Oncology, Inc. She previously worked as the Executive Director & Senior Corporate Counsel at Celgene Corp.
from 2017 to 2018.
She also worked as the Vice President & Assistant General Counsel at Bristol Myers Squibb Co. and as the Chief Legal & Compliance Officer at Genocea Biosciences, Inc. Ms. Sumer completed her undergraduate degree at Bucknell University and her graduate degree at Duke University School of Law.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 22/02/2024 | 94 133 ( 0.22% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Jacquelyn Sumer
| Società | Posizione | Inizio |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Compliance Officer | 15/08/2022 |
Precedenti posizioni note di Jacquelyn Sumer
| Società | Posizione | Fine |
|---|---|---|
| CELGENE | Director/Board Member | 01/07/2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Compliance Officer | - |
Formazione di Jacquelyn Sumer
| Bucknell University | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Borsa valori
- Insiders
- Jacquelyn Sumer
